<DOC>
	<DOCNO>NCT00252187</DOCNO>
	<brief_summary>The purpose study determine effect subcutaneous injection Human BNP ( nesiritide ) , hormone produce heart , pump ability heart , kidney function , hormonal function person heart failure .</brief_summary>
	<brief_title>Cardiac Hormone Replacement With Brain Natriuretic Peptide ( BNP ) Heart Failure</brief_title>
	<detailed_description>The cardiac hormone brain natriuretic peptide ( BNP ) play important role pathophysiology congestive heart failure ( CHF ) . Studies establish BNP mediates natriuresis , renin aldosterone ( RAAS ) inhibition , vasodilation lusitropism . Acute cardiac hormone replacement intravenous infusion BNP show possess potent vasodilating action human acute decompensated CHF result improvement clinical symptom . Natrecor ( nesiritide ) sterile , purify preparation human BNP approve FDA intravenous administration treatment patient acute decompensated congestive heart failure . However , chronic cardiac hormone replacement BNP therapeutic strategy CHF limit need administer BNP intravenously . The objective study define cardiorenal humoral action short term ( eight week ) chronic cardiac hormone replacement subcutaneous ( SQ ) BNP human NYHA class II-III CHF . Systolic diastolic function , leave ventricular remodel assessed volume , renal function , neurohumoral profiling exercise capacity assess prior eight week treatment .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>1 . Age &gt; 18 year 2 . Resting leave ventricular ejection fraction ( LVEF ) 35 % less ( determine within 48 month recruitment echocardiography , multiple gate acquisition scan ( MUGA ) leave ventriculogram . ) 3 . New York Heart Association ( NYHA ) Class I ( previous symptom heart failure ) , Class II III 4 . Female subject menopausal surgically sterilize need negative pregnancy test day study day contraception . 1 . Myocardial infarction ( MI ) within 3 month screen . 2 . Unstable angina within 14 day screen , evidence myocardial ischemia . 3 . Valvular stenosis , hypertrophic , restrictive obstructive cardiomyopathy , constrictive pericarditis , primary pulmonary hypertension , biopsy proven active myocarditis . 4 . Sustained ventricular tachycardia ( VT ) ventricular fibrillation ( Vfib ) within 14 day screen . 5 . Second third degree atrioventricular ( AV ) block without permanent cardiac pacemaker . 6 . Cerebrovascular accident ( CVA ) within 3 month screen , evidence significantly compromised central nervous system ( CNS ) perfusion . 7 . Serum creatinine &gt; 3.0 mg/dL . 8 . Serum sodium &lt; 125 milliequivalent per decaLiter ( mEq/dL ) &gt; 160 mEq/dL . 9 . Serum potassium &lt; 3.5 mEq/dL &gt; 5.2 mEq/dL . 10 . Serum digoxin level &gt; 2.0 ng/ml . 11 . Systolic pressure &lt; 85 mmHg immediately prior first injection study drug/placebo . 12 . LVEF &gt; 35 % within 24 month screen . 13 . Unable selfadminister subcutaneous injection twice day . 14 . Diagnosed AIDS know positive HIV titer . 15 . Other acute chronic medical condition laboratory abnormality , may increase risk , associate study participation may interfere interpretation data . 16 . Received investigational drug within 1 month prior dose . 17 . Unable undergo cardiac magnetic resonance imaging ( MRI ) . Contraindications MRI include pacemaker defibrillator , pregnant woman , atrial fibrillation arrhythmia , cerebral aneurysm clip , severe claustrophobia . 18 . In opinion investigator , unlikely comply study protocol unsuitable reason . 19 . Patient atrial fibrillation pacemaker implantable cardioverter defibrillator ( ICD ) 20 . Hemoglobin &lt; 10g/dl . 21 . Patients allergy iodine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Natriuretic peptide</keyword>
	<keyword>B-type natriuretic peptide</keyword>
	<keyword>Kidney</keyword>
	<keyword>Nesiritide</keyword>
	<keyword>Natrecor</keyword>
	<keyword>CHF</keyword>
</DOC>